Advertisement
U.S. markets close in 1 hour 18 minutes

Argent BioPharma Limited (H5O0.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.1720-0.0240 (-12.24%)
As of 08:06AM CEST. Market open.
Currency in EUR

Valuation Measures4

Market Cap (intraday) 11.59M
Enterprise Value 7.87M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)2.51
Price/Book (mrq)12.54
Enterprise Value/Revenue 7.64
Enterprise Value/EBITDA -0.82

Trading Information

Stock Price History

Beta (5Y Monthly) 1.05
52-Week Change 3-51.00%
S&P500 52-Week Change 337.82%
52 Week High 30.6260
52 Week Low 30.1120
50-Day Moving Average 30.1943
200-Day Moving Average 30.2018

Share Statistics

Avg Vol (3 month) 3180
Avg Vol (10 day) 32
Shares Outstanding 553.61M
Implied Shares Outstanding 659.13M
Float 820.36M
% Held by Insiders 116.48%
% Held by Institutions 11.02%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:1000
Last Split Date 3Oct 30, 2023

Financial Highlights

Currency in AUD.

Fiscal Year

Fiscal Year Ends Jun 30, 2024
Most Recent Quarter (mrq)Jun 30, 2024

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-3,425.64%

Management Effectiveness

Return on Assets (ttm)-108.57%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)891.08k
Revenue Per Share (ttm)0.02
Quarterly Revenue Growth (yoy)-59.80%
Gross Profit (ttm)N/A
EBITDA -16.97M
Net Income Avi to Common (ttm)-17.53M
Diluted EPS (ttm)-1.9800
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)702.87k
Total Cash Per Share (mrq)0.01
Total Debt (mrq)9.72M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.22
Book Value Per Share (mrq)-0.11

Cash Flow Statement

Operating Cash Flow (ttm)-14.66M
Levered Free Cash Flow (ttm)-7.22M